DEFINITION
The SURMOUNT programme is a series of randomised phase-3 clinical trials evaluating once-weekly subcutaneous Tirzepatide for weight management. SURMOUNT-1 (Jastreboff 2022) evaluated Tirzepatide versus placebo in adults with obesity or overweight with a weight-related complication, without type 2 diabetes.
The programme extends across additional populations and comparators. Primary endpoints centre on percent body-weight change and the proportion of participants achieving pre-specified weight-loss thresholds.
WHY IT MATTERS
SURMOUNT is the core evidence base for Tirzepatide as a weight-management pharmacotherapy.
RELATED
Compounds